Medical Management of Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Medical Management of Inflammatory Bowel Disease

Published:1989-12 Issue:12 Volume:23 Page:963-973
ISSN:1042-9611
Container-title:DICP
language:en
Short-container-title:DICP

Author:

Sottile Roseann F.¹,Quandt Christine M.²,Present Daniel H.³,Mehl Bernard⁴

Affiliation:

1. Mount Sinai Medical Center, Pennisula Hospital Center, Far Rockaway, NY

2. Department of Pharmacy, Mount Sinai Medical Center, Roerig Division, Pfizer Pharmaceuticals, New York, NY

3. Mount Sinai School of Medicine, One Gustave L. Levy PI., New York, NY 10029.

4. Department of Pharmacy, Mount Sinai Medical Center, One Gustave L. Levy PI., New York, NY 10029.

Abstract

Inflammatory bowel disease is a serious ailment that afflicts nearly one million people in the U.S. alone. The medical management of this disorder currently includes salicylates, corticosteroids, immunosuppressive therapy, and symptomatic treatment with antidiarrheal agents, although several promising new drugs have been developed. The epidemiology, etiology, pathogenesis, and medical management of the disease are discussed in this article.

Publisher

SAGE Publications

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Link

http://journals.sagepub.com/doi/pdf/10.1177/106002808902301202

Reference110 articles.

1. The immunologic basis of inflammatory bowel disease

2. Enhanced Synthesis of Leukotriene B4 by Colonic Mucosa in Inflammatory Bowel Disease

3. Recent Developments in Nonspecific Inflammatory Bowel Disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New developments in the pharmacotherapy of inflammatory bowel disease;Pharmaceutisch Weekblad Scientific Edition;1992-08

2. Eicosanoids and inflammatory bowel disease: Regulation and prospects for therapy;Prostaglandins, Leukotrienes and Essential Fatty Acids;1990-12